Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2015 by Stanford University
Sponsor:
Collaborator:
Seattle Genetics, Inc.
Information provided by (Responsible Party):
Youn Kim, Stanford University
ClinicalTrials.gov Identifier:
NCT01396070
First received: July 14, 2011
Last updated: February 5, 2015
Last verified: February 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: October 2015
  Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)